Novavax Inc. (NASDAQ:NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results. It is worth noting that Novavax has a short interest of 31.41% of its float.Novavax Q4 Profit ShiftNovavax reported a fourth-quarter earnings shift to a profit of 11 cents, compared to a loss of 51 cents a year ago, with revenue hitting $147 million, a 67% increase year-over-year.However, the compa ...

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Key Takeaways Novavax reported Q4 EPS of 11 cents, beating loss estimates as revenues rose 67% year over year.NVAX posted $108M in licensing revenues, including $98M under its Sanofi agreement.Novavax expects 2026 adjusted revenues of $230M-$270M, excluding Sanofi receivables.Novavax (NVAX) reported earnings of 11 cents per share in the fourth quarter of 2025 against the Zacks Consensus Estimate of a loss of 66 cents. In the year-ago quarter, the company had recorded a loss of 51 cents.Quarterly revenues to ...

Novavax Inc. (NASDAQ:NVAX) shares are up on Thursday following the company’s announcement of its fourth-quarter and full-year 2025 financial results.EarningsNovavax reported fourth-quarter earnings of 11 cents, a shift from a loss of 51 cents a year ago. evenue for the fourth quarter was $147 million, a 67% year-over-year increase.Novavax on Thursday said it beat its 2025 cost-cutting targets across both GAAP and Non-GAAP R&D and SG&A spending and is tightening future expense goals.The company now expects N ...

Novavax (NasdaqGS:NVAX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris LoBianco - VP of Equity ResearchElaine O'Hara - Chief Strategy OfficerJim Kelly - CFO and TreasurerJohn Jacobs - President and CEOLuis Sanay - VP of Investor RelationsMayank Mamtani - Senior Managing DirectorRuxandra Draghia - Head of R&DSean Lee - VP of Equity ResearchConference Call ParticipantsRoger Song - AnalystTom Shrader - Managing Director and Healthcare AnalystNone - AnalystNone - AnalystNone - Ana ...

Novavax (NasdaqGS:NVAX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Company ParticipantsChris LoBianco - VP of Equity ResearchElaine O'Hara - Chief Strategy OfficerJim Kelly - CFO and TreasurerJohn Jacobs - President and CEOLuis Sanay - VP of Investor RelationsMayank Mamtani - Senior Managing DirectorRuxandra Draghia - Head of R&DSean Lee - VP of Equity ResearchConference Call ParticipantsRoger Song - AnalystTom Shrader - Managing Director and Healthcare AnalystNone - AnalystNone - AnalystNone - Ana ...

Novavax (NasdaqGS:NVAX) Q4 2025 Earnings call February 26, 2026 08:30 AM ET Speaker6Welcome to Novavax Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star followed by 0. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then 1 on your touchtone phone. To withdraw your qu ...

Viatris forecasts 2026 profit below estimates on India manufacturing woes | ReutersSkip to main content[Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv]- Companies[Viatris Inc]Follow[Pfizer Inc]FollowFeb 26 (Reuters) - Drugmaker Viatris [(VTRS.O), opens new tab] forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations.A fire occurred at the company's manufacturing facility in Nashik, ...

Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights February 26, 2026 © 2026 NOVAVAX. All rights reserved This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate st ...

Skip to main content Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals Earlier this month, the U.S. Food and Drug Administration initially refused to review rival Moderna's (MRNA.O), opens new tab mRNA-based flu vaccine, then reversed course a week later after the company amended its application. The biotech now expects 2026 adjusted revenue of $230 million to $270 million, up from its prio ...